San Diego, California
November 3-6, 2025
Connect with Caris Life Sciences at World ADC 2025
Caris® Discovery is proud to join the World ADC 2025 Conference in San Diego, California. Meet with our team to learn how Caris Discovery is redefining novel discovery by bringing world-class science to the vast Caris tissue repository.
About Caris Discovery
Caris Discovery can partner on novel therapeutic target discovery, out-license our existing novel tumor targets, and validate target hypotheses with the Caris vast tissue database, Caris Multimodal Data, and Caris proprietary wet lab and bioinformatics technologies.
ADC Conference Session
Expanding the Novel ADC Target Landscape Through Multimodal Data-Informed Proteomics in Tumor Tissue
Wednesday, November 5, 2025
12:45PM (PT)
Presenter:
Milan Radovich, PHD
SVP & Chief Scientific Officer
Dr. Radovich will discuss how innovative proteomic platforms are uncovering masked targets and enabling the identification of high-confidence novel targets. He will also explore modality-agnostic strategies for validating ADC and other targets across indications, supported by multimodal insights from ~500K molecularly profiled tissue samples.
Schedule a Meeting
Products at a glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure™ delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Profile
MI Profile™ comprehensive testing delivers whole exome sequencing (WES – DNA) and whole transcriptome sequencing (WTS – RNA) for 23,000+ genes, as well as protein analysis and AI-predictive algorithms. The test is designed to reveal a complete molecular blueprint that can guide more precise and individualized treatment decisions that help improve patient outcomes.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Complete Molecular Intelligence Report
The Caris Molecular Profiling Report delivers high impact results, including potentially relevant, actionable clinical information, in an easy-to-interpret format. Every report includes access to the MI Portal and the Clinical Trials Connector™, which matches each patient’s unique biomarker expression profile to open, pertinent clinical trial opportunities.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.